S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Corindus Vascular Robotics Stock Price, News & Analysis (NYSEAMERICAN:CVRS)

$4.27
0.00 (0.00%)
(As of 11/27/2019)
Compare
Today's Range
$4.27
$4.27
50-Day Range
N/A
52-Week Range
$0.78
$4.40
Volume
N/A
Average Volume
1.99 million shs
Market Capitalization
$891.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CVRS stock logo

About Corindus Vascular Robotics Stock (NYSEAMERICAN:CVRS)

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

CVRS Stock Price History

CVRS Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Robotics & AI
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
CVRS_old Historical Data
Corindus Vascular Robotics Inc (CVRS_old)
IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS
See More Headlines
Receive CVRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corindus Vascular Robotics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2018
Today
12/06/2023

Industry, Sector and Symbol

Industry
Medical Appliances & Equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CVRS
Previous Symbol
NYSEMKT:CVRS
CIK
N/A
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$891.08 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Mark J. Toland (Age 49)
    CEO, Pres & Director
  • Mr. David W. Long (Age 49)
    CFO, Sr. VP, Sec. & Treasurer
  • Mr. Douglas Teany (Age 47)
    Chief Operating Officer
  • Ms. Nora Dutta
    Sr. VP of HR
  • Dr. J. Aaron Grantham
    Chief Medical Officer of Cardiovascular














CVRS Stock Analysis - Frequently Asked Questions

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings data on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical equipment provider earned $1.67 million during the quarter, compared to analyst estimates of $3 million.

What other stocks do shareholders of Corindus Vascular Robotics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (AMRN), Advanced Micro Devices (AMD), Micron Technology (MU), Alibaba Group (BABA), Helios and Matheson Analytics (HMNY), NVIDIA (NVDA), TherapeuticsMD (TXMD), Ambarella (AMBA) and Exelixis (EXEL).

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:CVRS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -